Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xtandi
Biotech
Astellas targets more deals, cost cutting to swerve patent cliff
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
James Waldron
May 26, 2026 7:35am
Fierce Pharma
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Pfizer shares prostate cancer data after leak, inks Alloy deal
Feb 11, 2025 1:07pm
Essa drops lead cancer drug after falling short against Xtandi
Nov 1, 2024 7:33am
Arvinas eyes a busy 2021 as protein degraders gather steam
Dec 14, 2020 10:32am
Astellas to halt work at R&D subsidiary amid restructuring plan
May 23, 2018 2:16pm
